Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024)

Protagonist Therapeutics (PTGX) has 4 years of Work In Process data on file, last reported at $165.0 million in Q4 2024.

• For the quarter ending Q4 2024, Work In Process rose 1550.0% year-over-year to $165.0 million; the trailing twelve-month figure through Dec 2024 stood at $165.0 million (up 1550.0% YoY), and the FY2024 full-year result was $165.0 million, up 1550.0% from the prior year.
• Work In Process advanced to $165.0 million in Q4 2024, from $43000.0 in the prior quarter.
• In the past five years, Work In Process ranged from a high of $300.0 million in Q1 2024 to a low of $10000.0 in Q4 2022.
• A 4-year average of $68.1 million and a median of $1.6 million in 2021 frame the typical range for Work In Process.
• Across the five-year window, Work In Process plunged 99.36% in 2022 and soared 99900.0% in 2023, its largest moves.
• Tracing PTGX's Work In Process over 4 years: stood at $1.6 million in 2021, then sank by 99.36% to $10000.0 in 2022, then soared by 99900.0% to $10.0 million in 2023, then surged by 1550.0% to $165.0 million in 2024.
• Business Quant data shows PTGX's Work In Process at $165.0 million in Q4 2024, $43000.0 in Q2 2024, and $300.0 million in Q1 2024.